ClinicalTrials.gg
Not yet recruitingNCT07609706Updated May 27, 2026

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

A Phase 1 interventional study of Belantamab mafodotin and Bortezomib in Multiple Myeloma, sponsored by GlaxoSmithKline. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Planned enrollment
35th of 49
20 · median 50
Started
2026
with 6 others
Phase 1
11 of 49
3 open now
Primary completion
2031-08
later than 31 of 34 live
Registered
45th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 35th largest by planned enrollment, is one of 7 that started in 2026, is one of 11 in phase 1, reaches primary completion later than 31 of the 34 other live ones, and was the 45th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal liver function. It also compares how liver problems affect the body's handling of belantamab mafodotin and uses the results to help set safe and appropriate dosing guidance for MM participants with moderate liver problems.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Hepatic Impairment
  • Bortezomib
  • Dexamethasone
  • Belantamab mafodotin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the form (ICF).
  • Has or cytologically confirmed diagnosis of MM, as defined by the International Myeloma Working Group (IMWG).
  • Previously treated with at least 1 prior line of MM therapy and must have documented disease progression during or after their most recent therapy.
  • Has at least 1 aspect of , defined as at least 1 of the following:

    1. Urine M-protein excretion ≥200 milligram (mg)/24 hours (≥0.2 gram [g]/24 hours)
    2. Serum M-protein concentration ≥0.5 g/ deciliter (dL) (≥5.0 g/L)
    3. Serum Free light chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65).
    4. Plasmacytoma measurable as per IMWG criteria
    5. Bone Marrow infiltration by plasma cells >30%
  • For those participants with a history of stem cell transplant, they are eligible for study participation provided the following eligibility criteria are met: transplant was >100 days prior to study enrollment; no active infection(s); participant meets the remainder of the eligibility criteria
  • All prior treatment-related toxicities (defined by National Cancer Institute [NCI-CTCAE] v5.0) must be Grade ≤1 at the time of treatment assignment, except for alopecia (any grade), neuropathy (Grade ≤2), or endocrinopathy managed with replacement therapy (any grade).
  • Is willing to use adequate male and female participants.
  • Female participants are eligible to participate if they are not pregnant or breastfeeding and meet additional requirements.
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
  • Has adequate organ function for hematological and renal function tests.
  • Has specific hepatic function ranges for serum and for Group 1 and Group 2.
  • Participants in Group 1 (normal hepatic function) will only be enrolled if they match a participant in Group 2 (moderate hepatic impairment). Each Group 1/Group 2 pair will be matched based on the Group 2 participant's baseline body weight (±20%).
  • Participants with a history of virus (HBV) and/or virus (HCV) and (HIV) exposure are eligible under specific conditions

Exclusion criteria

Exclusion Criteria:

  • Has an active plasma cell leukemia at the time of screening, symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes), or Waldenström macroglobulinemia.
  • Has a previous or concurrent invasive other than MM, except for any other disease from which the participant must be considered medically stable for at least 1 year; or the participant must not be receiving active therapy, other than hormonal therapy for this disease.
  • Known immediate or delayed reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Has evidence of active mucosal or internal bleeding.
  • Has a systemic active infection requiring treatment.
  • Has had any major surgery (other than bone-stabilizing surgery) within 28 days prior to the first dose of study treatment.
  • Has current corneal epithelial disease except for mild superficial keratopathy.
  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of , or compliance to the study procedures.
  • Has any history of prior allogenic stem cell transplant. Participants who have undergone syngeneic transplant will be allowed only if no history of or no currently active .
  • Has received prior belantamab mafodotin therapy if given within the last 90 days.
  • Has received treatment with an agent within 14 days or 5 half-lives, whichever is shorter, preceding the first dose of study drug. This includes prior treatment with a monoclonal antibody and any other B-cell maturation antigen (BCMA) targeting therapy. The only exception is emergency use of a short course of systemic (equivalent to, or less than: dexamethasone 40 mg/day for a maximum of 4 days) before treatment.
  • Has received treatment with an inhibitor of Organic anion transporting polypeptide (OATP)1B1 or OATP1B3 within 14 days, preceding the first dose of study drug.
  • Has received plasmapheresis within 7 days prior to the first dose of study treatment. Screening laboratory values must be performed after last plasmapheresis.
  • Has received any within 30 days of enrollment. Vaccination against COVID-19 using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.
  • Has a known infection, unless the participant meets all of the following criteria:

    1. Established Anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \<400 copies/milliliter (mL) prior to first dose.
    2. Has values ≥350 cells/L
    3. No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months.
  • Is pregnant, plans to become pregnant, or is breastfeeding.
  • Has Gilbert's syndrome.
  • Has current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice in the last 14 days prior to the first dose.
  • Has documented presence of surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to the first dose of study intervention. Participants with hepatitis B will be excluded unless the specific protocol criteria are met.
  • Has a positive virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention unless HCV ribonucleic acid (RNA) is negative, indicating past resolved HCV infection, including participants who have undergone curative treatment, unless specific protocol criteria are met
  • Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention.
  • Evidence of cardiovascular risk including any of the following:

    1. Evidence of current untreated arrhythmias, including clinically significant (ECG) abnormalities including second degree (Mobitz Type II) or third degree atrioventricular block.
    2. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening.
    3. Class III or IV heart failure as defined by the (NYHA) functional classification system.
    4. Uncontrolled hypertension.
  • Has corrected (QTc) >450 milliseconds (msec) or QTc >480 msec for participants with bundle branch block
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Normal hepatic function

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Moderate hepatic impairment

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time 0 to the end of the dosing interval (AUC 0-tau) of belantamab mafodotin antibody drug conjugate (ADC)

    Time frame: Up to 3 weeks

  2. Maximum observed plasma concentration (Cmax) of belantamab mafodotin ADC

    Time frame: Up to 3 weeks

  3. Concentration at end of infusion (C-EOI) of belantamab mafodotin ADC

    Time frame: Up to 104 weeks

  4. Drug concentration reached prior to next dose (Ctrough) of belantamab mafodotin ADC

    Time frame: Up to 104 weeks

  5. Time to reach Cmax (Tmax) of belantamab mafodotin ADC

    Time frame: Up to 3 weeks

  6. Area under the plasma concentration-time curve from time 0 to 168 hours (AUC 0-168h) of microtubule inhibitor released from belantamab mafodotin (cys-mcMMAF)

    Time frame: Up to 168 hours

  7. Area under the plasma concentration-time curve from time 0 to 240 hours (AUC 0-240h) of cys-mcMMAF

    Time frame: Up to 240 hours

  8. Cmax of cys-mcMMAF

    Time frame: Up to 3 weeks

  9. Tmax of cys-mcMMAF

    Time frame: Up to 3 weeks

Secondary outcomes

  1. Number of participants with adverse events (AEs) and serious AEs by severity

    Time frame: Up to 252 weeks

  2. Number of participants with AEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to 252 weeks

  3. Number of participants with changes in visual acuity (VA) and corneal findings by severity as assessed by Keratopathy Visual Acuity scale (KVA) scale

    The Keratopathy-Visual Acuity (KVA) scale is a 0-4 grading system used to assess the severity of keratopathy and its impact on visual acuity. Higher grades reflect increasing severity of corneal findings and visual acuity loss.

    Time frame: Up to 252 weeks

  4. Number of participants with ocular AEs by severity as assessed by Common terminology criteria for adverse events (CTCAE)

    Time frame: Up to 252 weeks

  5. Number of participants with thrombocytopenic events by severity

    Time frame: Up to 252 weeks

  6. Change from baseline in clinical laboratory parameter: serum bilirubin (milligrams per decilitre[mg/dl])

    Time frame: Baseline (Day 1) and up to 252 weeks

  7. Change from baseline in clinical laboratory parameter: AST and ALT (International Units per litre [IU/L])

    Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) will be analysed. Both parameters have same unit of measure.

    Time frame: Baseline (Day 1) and up to 252 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2031, 57 months later.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 57 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartEst.
Oct 23, 2026
Primary completionEst.
Aug 22, 2031
CompletionEst.
Aug 22, 2031
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07609706
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Oct 23, 2026 (estimated)
Primary completion
Aug 22, 2031 (estimated)
Completion
Aug 22, 2031 (estimated)
Last update
May 27, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belantamab mafodotin · Bortezomib · Dexamethasone

Start the discussion